(i) We focused on drug combinations involving the protein BRAF in colorectal cancer, which is frequently mutated in this cancer type (~10% of The Cancer Genome Atlas (TCGA) patients20) and can result in uncontrolled, non-EGFR-dependent cellular proliferation21. This evidence concerns the gene BRAF and cancer.